These cost more but provide the holistic approach that research shows produces better long-term outcomes
At this time, it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027, pending further action from CMS to implement the BALANCE Model in Medicare Part D in 2028, as described below
Insurance covers GLP-1 medications, but coverage extent varies by your provider, location, and health circumstances
Symptom-Triggered Testing Persistent severe abdominal pain: urgent evaluation, lipase testing, and appropriate imaging Right-upper-abdominal pain or jaundice: liver and biliary testing plus gallbladder imaging Persistent vomiting or diarrhea: kidney function and electrolyte testing Symptoms of hypoglycemia: immediate glucose evaluation Fatigue or signs of deficiency: CBC and selected nutritional tests Testing should not delay medical care for severe symptoms
17 To put these improvements in context, the current standard of care, acetazolamide, was studied in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)
Hippocampal insulin resistance and cognitive dysfunction